Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience

The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactions allows the use of nab-paclitaxel in patients wh...

Full description

Bibliographic Details
Main Authors: E. I. Borisova, S. P. Gutorov, G. V. Vyshinskaya, N. V. Dobrova, M. E. Abramov
Format: Article
Language:Russian
Published: Remedium Group LLC 2018-11-01
Series:Медицинский совет
Subjects:
nab-paclitaxel
breast cancer
chemotherapy
Online Access:https://www.med-sovet.pro/jour/article/view/2747
id doaj-828fe9378db24020b033974b516a9be6
record_format Article
spelling doaj-828fe9378db24020b033974b516a9be62021-07-28T13:29:38ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-11-01019566010.21518/2079-701X-2018-19-56-602689Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experienceE. I. Borisova0S. P. Gutorov1G. V. Vyshinskaya2N. V. Dobrova3M. E. Abramov4Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, MoscowBlokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, MoscowThe article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactions allows the use of nab-paclitaxel in patients who had reactions with the introduction of traditional taxanes and in the presence of contraindications to corticosteroids premedication. The absence of cross-resistance makes possible to prescribe nabpaclitaxel in patients who had progression on treatment with paclitaxel and docetaxel. The cases of effective use of the drug from our own practice are presented.https://www.med-sovet.pro/jour/article/view/2747nab-paclitaxelbreast cancerchemotherapy
collection DOAJ
language Russian
format Article
sources DOAJ
author E. I. Borisova
S. P. Gutorov
G. V. Vyshinskaya
N. V. Dobrova
M. E. Abramov
spellingShingle E. I. Borisova
S. P. Gutorov
G. V. Vyshinskaya
N. V. Dobrova
M. E. Abramov
Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
Медицинский совет
nab-paclitaxel
breast cancer
chemotherapy
author_facet E. I. Borisova
S. P. Gutorov
G. V. Vyshinskaya
N. V. Dobrova
M. E. Abramov
author_sort E. I. Borisova
title Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
title_short Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
title_full Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
title_fullStr Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
title_full_unstemmed Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
title_sort nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2018-11-01
description The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactions allows the use of nab-paclitaxel in patients who had reactions with the introduction of traditional taxanes and in the presence of contraindications to corticosteroids premedication. The absence of cross-resistance makes possible to prescribe nabpaclitaxel in patients who had progression on treatment with paclitaxel and docetaxel. The cases of effective use of the drug from our own practice are presented.
topic nab-paclitaxel
breast cancer
chemotherapy
url https://www.med-sovet.pro/jour/article/view/2747
work_keys_str_mv AT eiborisova nabpaclitaxelinthetreatmentofbreastcancerclinicaltrialdataandfirsthandexperience
AT spgutorov nabpaclitaxelinthetreatmentofbreastcancerclinicaltrialdataandfirsthandexperience
AT gvvyshinskaya nabpaclitaxelinthetreatmentofbreastcancerclinicaltrialdataandfirsthandexperience
AT nvdobrova nabpaclitaxelinthetreatmentofbreastcancerclinicaltrialdataandfirsthandexperience
AT meabramov nabpaclitaxelinthetreatmentofbreastcancerclinicaltrialdataandfirsthandexperience
_version_ 1721273950011392000

Similar Items